SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-010057
Filing Date
2023-04-12
Accepted
2023-04-12 08:50:25
Documents
15
Period of Report
2023-04-05
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20230411_8k.htm   iXBRL 8-K 30074
2 EXHIBIT 99.1 ex_499929.htm EX-99.1 20228
7 ex_499929img001.jpg GRAPHIC 5317
  Complete submission text file 0001437749-23-010057.txt   199082

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbla-20230405.xsd EX-101.SCH 3602
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20230405_def.xml EX-101.DEF 11533
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20230405_lab.xml EX-101.LAB 15415
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20230405_pre.xml EX-101.PRE 11689
9 EXTRACTED XBRL INSTANCE DOCUMENT pbla20230411_8k_htm.xml XML 2554
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

IRS No.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 23814731
SIC: 2834 Pharmaceutical Preparations